Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ARS Pharmaceuticals Inc | SPRY | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.88 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.88 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.55 - 11.27 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 8.88 | USD |
ARS Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 860.43M | - | - | - | -15.83 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ARS Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.10 | 9.30 | 8.77 | 8.91 | 465,617 | -0.22 | -2.42% |
| 1 Month | 9.75 | 9.80 | 8.59 | 9.00 | 354,066 | -0.87 | -8.92% |
| 3 Months | 8.59 | 11.27 | 7.66 | 9.15 | 613,844 | 0.29 | 3.38% |
| 6 Months | 4.94 | 11.27 | 4.94 | 8.15 | 535,772 | 3.94 | 79.76% |
| 1 Year | 7.23 | 11.27 | 2.55 | 5.93 | 751,692 | 1.65 | 22.82% |
| 3 Years | 5.28 | 11.27 | 2.55 | 6.58 | 761,810 | 3.60 | 68.18% |
| 5 Years | 5.28 | 11.27 | 2.55 | 6.58 | 761,810 | 3.60 | 68.18% |
ARS Pharmaceuticals Description
| ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. |
